EP3288585A4 - Neuartige zusammensetzungen und verfahren für immuntherapien mit agonist-adjuvanzien mit kleinmoleküligem integrin-rezeptorligand - Google Patents

Neuartige zusammensetzungen und verfahren für immuntherapien mit agonist-adjuvanzien mit kleinmoleküligem integrin-rezeptorligand Download PDF

Info

Publication number
EP3288585A4
EP3288585A4 EP16787110.2A EP16787110A EP3288585A4 EP 3288585 A4 EP3288585 A4 EP 3288585A4 EP 16787110 A EP16787110 A EP 16787110A EP 3288585 A4 EP3288585 A4 EP 3288585A4
Authority
EP
European Patent Office
Prior art keywords
immunotherapies
methods
small molecule
novel compositions
integrin receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16787110.2A
Other languages
English (en)
French (fr)
Other versions
EP3288585A2 (de
Inventor
Darren G. Woodside
Peter Vanderslice
Upendra K. Marathi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas Heart Institute
7 Hills Interests LLC
Original Assignee
Texas Heart Institute
7 Hills Interests LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas Heart Institute, 7 Hills Interests LLC filed Critical Texas Heart Institute
Priority claimed from PCT/US2016/029683 external-priority patent/WO2016176400A2/en
Publication of EP3288585A2 publication Critical patent/EP3288585A2/de
Publication of EP3288585A4 publication Critical patent/EP3288585A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP16787110.2A 2015-04-29 2016-04-28 Neuartige zusammensetzungen und verfahren für immuntherapien mit agonist-adjuvanzien mit kleinmoleküligem integrin-rezeptorligand Pending EP3288585A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154554P 2015-04-29 2015-04-29
PCT/US2016/029683 WO2016176400A2 (en) 2015-04-29 2016-04-28 Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants

Publications (2)

Publication Number Publication Date
EP3288585A2 EP3288585A2 (de) 2018-03-07
EP3288585A4 true EP3288585A4 (de) 2019-05-01

Family

ID=61024178

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16787110.2A Pending EP3288585A4 (de) 2015-04-29 2016-04-28 Neuartige zusammensetzungen und verfahren für immuntherapien mit agonist-adjuvanzien mit kleinmoleküligem integrin-rezeptorligand

Country Status (1)

Country Link
EP (1) EP3288585A4 (de)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068251A2 (en) * 2010-11-16 2012-05-24 Texas Heart Institute Agonists that enhance binding of integrin-expressing cells to integrin receptors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068251A2 (en) * 2010-11-16 2012-05-24 Texas Heart Institute Agonists that enhance binding of integrin-expressing cells to integrin receptors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALESSANDRA TOLOMELLI ET AL: "Can Integrin Agonists Have Cards to Play against Cancer? A Literature Survey of Small Molecules Integrin Activators", CANCERS, vol. 9, no. 12, 5 July 2017 (2017-07-05), pages 78, XP055531258, DOI: 10.3390/cancers9070078 *
ANDREW M. SCOTT ET AL: "Antibody therapy of cancer", NATURE REVIEWS. CANCER, vol. 12, no. 4, 1 April 2012 (2012-04-01), GB, pages 278 - 287, XP055531673, ISSN: 1474-175X, DOI: 10.1038/nrc3236 *
M. A. SCHWARTZ ET AL: "Integrin Agonists as Adjuvants in Chemotherapy for Melanoma", CLINICAL CANCER RESEARCH, vol. 14, no. 19, 1 October 2008 (2008-10-01), US, pages 6193 - 6197, XP055531739, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-08-1285 *
SIMON L GOODMAN ET AL: "Integrins as therapeutic targets", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 33, no. 7, 1 July 2012 (2012-07-01), pages 405 - 412, XP028495741, ISSN: 0165-6147, [retrieved on 20120412], DOI: 10.1016/J.TIPS.2012.04.002 *

Also Published As

Publication number Publication date
EP3288585A2 (de) 2018-03-07

Similar Documents

Publication Publication Date Title
EP3350165A4 (de) Farnesoid-x-rezeptoragonisten und verwendungen davon
EP3355954A4 (de) Freisetzungsverfahren und zusammensetzungen
EP3337907A4 (de) Auf mikrotropfen basierende verfahren für multiple-displacement-amplifikation (mda) und zugehörige zusammensetzungen
EP3350164A4 (de) Farnesoid-x-rezeptoragonisten und verwendungen davon
EP3350166A4 (de) Farnesoid-x-rezeptoragonisten und verwendungen davon
EP3548476A4 (de) Kleinmolekülige ire1-inhibitoren
EP3099677A4 (de) Diaminopyrimidinbenzolsulfonderivate und verwendungen davon
IL255297A0 (en) New compounds and methods for immunotherapies containing small molecules that are agonistic adjuvants of the integrin-ligand receptor
EP3316909A4 (de) Anti-ntb-a-antikörper sowie zugehörige zusammensetzungen und verfahren
EP3350158A4 (de) Farnesoid-x-rezeptoragonisten und verwendungen davon
EP3380970A4 (de) Neuartige azolderivate als apelin-rezeptoragonisten
EP3129048A4 (de) Antikörper, pharmazeutische zusammensetzungen und verwendungen davon
EP3503879A4 (de) Zusammensetzung und verfahren dafür
EP3352800A4 (de) Verfahren und zusammensetzungen zur reduktion von metastasen
EP3150578A4 (de) Neuartige pyrrolidinderivate und anwendung als melanocortinrezeptoragonist
EP3442543A4 (de) Zusammensetzungen und verfahren für neurogenese
EP3436083A4 (de) Neuartige zusammensetzungen und verfahren
EP3096757A4 (de) Apilimodzusammensetzungen und verfahren zur verwendung davon
EP3319938A4 (de) Niedermolekulare inhibitoren des mcl-1-onkoproteins und verwendungen davon
EP3230302A4 (de) Trägermolekülzusammensetzungen und zugehörige verfahren
EP3253389A4 (de) Apilimodzusammensetzungen und verfahren zur verwendung davon
EP3706558A4 (de) Zusammensetzungen und verfahren für aquakultur
EP3217978A4 (de) Zusammensetzungen mit substituiertem benzofurochinolizin und alpha2-adrenergischen agonisten
EP3160961A4 (de) Kleinmolekülige agonisten des neurotensinrezeptors 1
EP3202759A4 (de) Alpha-aminoamid-derivat-verbindung und pharmazeutische zusammensetzung damit

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171113

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: 7 HILLS INTERESTS, LLC

Owner name: TEXAS HEART INSTITUTE

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/16 20060101ALI20181213BHEP

Ipc: A61K 39/39 20060101ALI20181213BHEP

Ipc: A61K 31/381 20060101ALI20181213BHEP

Ipc: A61K 39/00 20060101AFI20181213BHEP

Ipc: A61K 31/36 20060101ALI20181213BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20190401

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/36 20060101ALI20190326BHEP

Ipc: A61K 31/381 20060101ALI20190326BHEP

Ipc: A61K 39/00 20060101AFI20190326BHEP

Ipc: A61K 39/39 20060101ALI20190326BHEP

Ipc: A61K 31/16 20060101ALI20190326BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200616

R17C First examination report despatched (corrected)

Effective date: 20200717

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS